Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients

Journal of Obstetrics and Gynaecology

Volumn 22, Issue 3, 2002, Pages 312-313

  Lehoczky, Otto ^a   Bagaméri, Andrea ^a   Udvary, J ^a   Pulay, T ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANGIONEUROTIC EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; DISEASE SEVERITY; DYSPNEA; EXPERIENCE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; OVARY CANCER; PREMEDICATION; PRIORITY JOURNAL;

AGED; ANAPHYLAXIS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0036283117     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610220130661     Document Type: Article

References (8)

1. Paclitaxel-associated hypersensitivity reactions: Experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center
2. Combined carboplatin and weekly paclitaxel (P) chemotherapy for recurrent gynecologic malignancies
3. Taxol hypersensitivity: Rapid retreatment is safe and cost effective
4. Phase I study of weekly paclitaxel and weekly carboplatin in gynecologic Oncology Group Kyushu
5. Successful re-treatment with taxol after major hypersensitivity reactions
6. Randomised intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
7. Rapid retreatment is safe and cost effective in taxol hypersensitivity reactions
8. Hypersensitivity reactions from taxol